Regenerative Medical Technology Group Inc. (RMTG)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 1.5M 3M 4.5M Q1 '18: 17.7K Q2 '18: 8.9K Q3 '18: 11.7K Q4 '18: 11.8K Q1 '19: 11.9K Q2 '19: 7.2K Q3 '19: 6.2K Q4 '19: 4.8K Q1 '20: 11.3K Q2 '20: 28.8K Q3 '20: 12.3K Q4 '20: 2.7K Q1 '21: 4.4K Q2 '21: 15.8K Q3 '21: 165K Q4 '21: 252.6K Q1 '22: 298.7K Q2 '22: 297.5K Q3 '22: 367.7K Q4 '22: 566.3K Q1 '23: 786.2K Q2 '23: 361.4K Q3 '23: 646.8K Q4 '23: 615.6K Q1 '24: 817K Q2 '24: 793.3K Q3 '24: 986.3K Q4 '24: 1.5M Q1 '25: 1.4M Q2 '25: 983.3K Q3 '25: 1.2M Q4 '25: 1.6M Q1 '26: 2.6M Q2 '26: 4M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

-900K 0 900K 1.8M 2.7M Q1 '18: 13.2K Q2 '18: 3.2K Q3 '18: 4.9K Q1 '19: -3.8K Q2 '19: -7.8K Q3 '19: -15.8K Q4 '19: 2K Q1 '20: -799 Q2 '20: 9.9K Q3 '20: 1.9K Q4 '20: 184 Q1 '21: -10.3K Q2 '21: 3.9K Q3 '21: 76.5K Q4 '21: 80.1K Q1 '22: 106.3K Q2 '22: 147K Q3 '22: 264.9K Q4 '22: 358.8K Q1 '23: 536.8K Q2 '23: 253.8K Q3 '23: 450.3K Q4 '23: 434.7K Q1 '24: 569K Q2 '24: 526.9K Q3 '24: 747.1K Q4 '24: 980.2K Q1 '25: 943.9K Q2 '25: 585.6K Q3 '25: 501.6K Q4 '25: 779.5K Q1 '26: 1.8M Q2 '26: 2.6M Q3 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Income Quarterly

-600K -400K -200K 0 200K 400K 600K Q1 '24: -105.1K Q2 '24: -214K Q3 '24: 19.6K Q4 '24: 380.6K Q1 '25: 135K Q2 '25: -250.1K Q3 '25: -445.8K Q4 '25: -306.3K Q1 '26: 229.8K Q2 '26: 566K Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Net Income Quarterly

-10.5M -7M -3.5M 0 3.5M 7M 10.5M Q1 '18: -138.2K Q2 '18: 34.2K Q3 '18: -628.3K Q4 '18: -1.3M Q1 '19: -2.7M Q2 '19: 2.9M Q3 '19: -1.7M Q4 '19: -1M Q1 '20: -846.3K Q2 '20: -3.4M Q3 '20: -7.4M Q4 '20: 5.7M Q1 '21: -472.3K Q2 '21: -926.1K Q3 '21: -9.9M Q4 '21: -1.6M Q1 '22: -1.7M Q2 '22: -1.5M Q3 '22: -1.3M Q4 '22: -992.4K Q1 '23: -1.7M Q2 '23: -2M Q3 '23: -5.9M Q4 '23: -256K Q1 '24: -2M Q2 '24: -2.1M Q3 '24: -887.1K Q4 '24: -638.2K Q1 '25: -760K Q2 '25: -1.4M Q3 '25: -4.4M Q4 '25: -1.4M Q1 '26: -876.3K Q2 '26: -2.9M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

0 500K 1M 1.5M Q1 '18: 4.5K Q2 '18: 5.7K Q3 '18: 6.8K Q4 '18: 51.4K Q1 '19: 15.7K Q2 '19: 15K Q3 '19: 22K Q4 '19: 2.8K Q1 '20: 12.1K Q2 '20: 18.9K Q3 '20: 10.4K Q4 '20: 2.5K Q1 '21: 14.8K Q2 '21: 11.9K Q3 '21: 88.5K Q4 '21: 172.6K Q1 '22: 192.5K Q2 '22: 150.6K Q3 '22: 102.8K Q4 '22: 207.4K Q1 '23: 249.4K Q2 '23: 107.5K Q3 '23: 196.5K Q4 '23: 180.8K Q1 '24: 248K Q2 '24: 266.4K Q3 '24: 239.2K Q4 '24: 530.6K Q1 '25: 420.4K Q2 '25: 397.7K Q3 '25: 679K Q4 '25: 792.4K Q1 '26: 872.9K Q2 '26: 1.4M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow Quarterly

-9M -6M -3M 0 3M 6M 9M Q1 '18: -34.9K Q2 '18: -67.6K Q3 '18: -68.2K Q4 '18: -73.9K Q1 '19: -92.6K Q2 '19: -86.6K Q3 '19: -134.7K Q4 '19: -48.5K Q1 '20: -64.7K Q2 '20: -69K Q3 '20: -92.1K Q4 '20: -96.9K Q1 '21: -154.9K Q2 '21: -544.3K Q3 '21: -430.7K Q4 '21: -8.7M Q1 '22: -516.1K Q2 '22: -396.4K Q3 '22: -152.2K Q4 '22: -49.4K Q1 '23: 6.8K Q2 '23: -406.7K Q3 '23: 10.1K Q4 '23: -29.4K Q1 '24: 108K Q2 '24: 90.4K Q3 '24: 272.9K Q4 '24: 379.4K Q1 '25: 57.1K Q2 '25: -598.1K Q3 '25: -203.7K Q4 '25: 38.2K Q1 '26: 102.1K Q2 '26: 332K Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-450K -300K -150K 0 150K 300K 450K Q4 '18: -73.9K Q1 '19: -192.6K Q2 '19: -86.6K Q3 '19: -134.7K Q4 '19: -48.5K Q1 '20: -164.7K Q2 '20: -69K Q3 '20: -92.1K Q4 '20: -96.9K Q1 '21: -254.9K Q3 '22: -153.4K Q4 '22: -118K Q1 '23: 1.3K Q2 '23: -411.4K Q3 '23: -81.2K Q4 '23: -313.4K Q1 '24: 48.8K Q2 '24: 37.7K Q3 '24: 219.3K Q4 '24: 329.4K Q3 '25: -428.6K Q4 '25: -229K Q1 '26: -213.3K Q2 '26: 288.5K Q2 '19 Q1 '20 Q4 '20 Q4 '22 Q3 '23 Q2 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q2 '18: 22.8M Q3 '18: 3.9M Q1 '19: 4.9M Q2 '19: 66.6M Q3 '19: 5.1M Q1 '20: 8.3M Q2 '20: 8.7M Q3 '20: 9.9M Q1 '21: 10.9M Q2 '21: 10.9M Q3 '21: 12M Q1 '22: 12.1M Q2 '22: 12.2M Q3 '22: 12M Q1 '23: 12.4M Q2 '23: 12.4M Q3 '23: 12.4M Q1 '24: 12.5M Q2 '24: 12.5M Q3 '24: 12.5M Q1 '25: 12.5M Q2 '25: 12.5M Q3 '25: 12.5M Q1 '26: 13.1M Q2 '26: 13.2M Q2 '18 Q3 '19 Q1 '21 Q2 '22 Q3 '23 Q1 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.50 -1.00 -0.50 0.00 0.50 1.00 1.50 Q4 '19: -0.47 Q1 '20: 0.01 Q2 '20: -0.42 Q3 '20: -0.83 Q4 '20: -0.63 Q1 '21: -0.57 Q2 '21: -0.26 Q3 '21: -0.33 Q4 '21: -1.06 Q1 '22: -1.16 Q2 '22: -1.20 Q3 '22: -0.49 Q4 '22: -0.45 Q1 '23: -0.44 Q2 '23: -0.48 Q3 '23: -0.84 Q4 '23: -0.78 Q1 '24: -0.81 Q2 '24: -0.82 Q3 '24: -0.42 Q4 '24: -0.45 Q1 '25: -0.35 Q2 '25: -0.30 Q3 '25: -0.58 Q4 '25: -0.64 Q1 '26: -0.65 Q2 '26: -0.75 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.